Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer
Anti-PD-1 antibodies combined with lenvatinib and GEMOX chemotherapy are effective and well-tolerated as a non-first-line therapy in advanced GBC. PD-L1 expression and baseline NLR may potentially predict treatment efficacy.
Authors
- Yang Tan
- Jiashuo Chao (ORCID: https://orcid.org/0000-0002-6578-5967)
- Daobing Zeng (ORCID: https://orcid.org/0000-0001-9675-5659)
- Chengpei Zhu (ORCID: https://orcid.org/0000-0002-0291-782X)
- Cong Ning
- Jingnan Xue
- Longhao Zhang
- Haitao Zhao (ORCID: https://orcid.org/0000-0002-3444-8044)
- Kai Liu (ORCID: https://orcid.org/0009-0006-1211-0399)
- Nan Zhang (ORCID: https://orcid.org/0000-0001-7667-0615)
- Shanshan Wang (ORCID: https://orcid.org/0000-0001-7364-768X)
- Lijin Zhao (ORCID: https://orcid.org/0000-0002-7741-5074)
- Junyu Long (ORCID: https://orcid.org/0000-0001-5745-7165)
- Xiaobo Yang (ORCID: https://orcid.org/0000-0001-6164-4131)
- Yunchao Wang
Institutions
- Zunyi Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Beijing YouAn Hospital (CN)
- Affiliated Hospital of Zunyi Medical College (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1007/s00262-024-03831-1
- Citations
- 3
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- National Natural Science Foundation of China
- Guizhou Science and Technology Department
- Peking Union Medical College Hospital
- Chinese Society of Clinical Oncology
- National Ten Thousand Talent Program